Today we bring back our popular Journal Club with a Fellow segment. We're joined by Dr. Karine Tawagi of the Oschner Clinic in Louisiana to discuss the CLEAR trial: "Lenvatinib plus Pembrolizumab or Everolimus for Advanced Renal Cell Carcinoma" as published in the New England Journal of Medicine.
3.86 Lenvatinib plus Pembrolizumab or Everolimus for Advanced RCC with Dr. Karine Tawagi
Previous
Previous
3.87 Round Table on Multiple Myeloma Initial Therapy, High Risk, and Maintenance
Next
Next